Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma

PHASE4CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

January 31, 2010

Study Completion Date

June 30, 2010

Conditions
Multiple Myeloma
Interventions
DRUG

Bortezomib

Bortezomib, 1,3 mg/ m2 iv twice a week in combination with Melfalán 9 mg/m2 oral, days 1 to 4 and Prednisone, 60 mg/m2 oral, days 1 to 4

DRUG

Thalidomide

Thalidomide, day 1 cycle 1, 100 mg/24 h. oral, in combination with cyclophosphamide and dexamethasone. If toxicity is \<Grade 2, dose should be increased to 200 mg/24 h. in day 15

DRUG

Bortezomib

Bortezomib, 1,3 mg/ m2 iv twice a week in combination with Melfalán 9 mg/m2 oral, days 1 to 4, Prednisone, 60 mg/m2 oral, days 1 to 4 and Adriamicine, 40 mg/m2 IV day 1 or Caelyx 30 mg/m2 IV day 1.

Trial Locations (5)

Unknown

Hospital Morales Messeguer, Murcia

Hospital Virgen de la Vega, Murcia

Hospital de la Diputación de Navarra, Navarra

Hospital Clínico de Salamanca, Salamanca

Hospital La Fe, Valencia

All Listed Sponsors
lead

PETHEMA Foundation

OTHER

NCT00652041 - Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma | Biotech Hunter | Biotech Hunter